Table of Contents Author Guidelines Submit a Manuscript
International Journal of Vascular Medicine
Volume 2011, Article ID 250518, 5 pages
http://dx.doi.org/10.1155/2011/250518
Review Article

Diabetes Mellitus and Cardiovascular Prevention: The Role and the Limitations of Currently Available Antiplatelet Drugs

Regional Reference Centre for Coagulation Disorders, Department of Clinical and Experimental Medicine, University of Naples Federico II, 80131 Naples, Italy

Received 21 March 2011; Accepted 3 May 2011

Academic Editor: Karlheinz Peter

Copyright © 2011 A. Tufano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. W. Nesto, “Correlation between cardiovascular disease and diabetes mellitus: current concepts,” American Journal of Medicine, vol. 116, supplement 5, pp. 11S–22S, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. P. Ferroni, S. Basili, A. Falco, and G. Davi, “Platelet activation in type 2 diabetes mellitus,” Journal of Thrombosis and Haemostasis, vol. 2, no. 8, pp. 1282–1291, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. D. Tschoepe, P. Roesen, B. Schwippert, and F. A. Gries, “Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis,” Seminars in Thrombosis and Hemostasis, vol. 19, no. 2, pp. 122–128, 1993. View at Google Scholar · View at Scopus
  4. R. Demirtunc, D. Duman, M. Basar, M. Bilgi, M. Teomete, and T. Garip, “The relationship between glycemic control and platelet activity in type 2 diabetes mellitus,” Journal of Diabetes and Its Complications, vol. 23, no. 2, pp. 89–94, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. P. D. Winocour, “Platelets, vascular disease, and diabetes mellitus,” Canadian Journal of Physiology and Pharmacology, vol. 72, no. 3, pp. 295–303, 1994. View at Google Scholar · View at Scopus
  6. J. M. Bridges, A. M. Dalby, J. H. D. Millar, and J. A. Weaver, “An effect of d-glucose on platelet stickiness,” The Lancet, vol. 285, no. 7376, pp. 75–77, 1965. View at Google Scholar · View at Scopus
  7. J. A. Colwell and R. W. Nesto, “The platelets in diabetes: focus on prevention of ischemic events,” Diabetes Care, vol. 26, no. 7, pp. 2181–2188, 2003. View at Google Scholar · View at Scopus
  8. C. Watala, M. Boncler, and P. Gresner, “Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus,” Pharmacological Reports, vol. 57, pp. 42–58, 2005. View at Google Scholar · View at Scopus
  9. D. J. Angiolillo, “Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions,” Diabetes Care, vol. 32, no. 4, pp. 531–540, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. Antithrombotic Trialists' (ATT) Collaboration, “Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials,” The Lancet, vol. 373, no. 9678, pp. 1849–1860, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. B. Buse, H. N. Ginsberg, G. L. Bakris et al., “Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association,” Circulation, vol. 115, no. 1, pp. 114–126, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. J. B. Buse, H. N. Ginsberg, G. L. Bakris et al., “Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association,” Diabetes Care, vol. 30, no. 1, pp. 162–172, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. T. A. Pearson, S. N. Blair, S. R. Daniels, R. H. Eckel, J. M. Fair, S. P. Fortmann et al., “AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases (AHA scientific statement),” Circulation, vol. 106, no. 3, pp. 388–391, 2002. View at Publisher · View at Google Scholar
  14. L. Ryden, E. Standl, M. Bartnik et al., “Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD),” European Heart Journal, vol. 28, no. 1, pp. 88–136, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. H. Ogawa, M. Nakayama, T. Morimoto et al., “Low-dose Aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial,” Journal of the American Medical Association, vol. 300, no. 18, pp. 2134–2141, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. J. Belch, A. MacCuish, I. Campbell et al., “The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of Aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease,” British Medical Journal, vol. 337, article a1840, 2008. View at Google Scholar
  17. G. De Berardis, M. Sacco, G. F. M. Strippoli et al., “Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials,” British Medical Journal, vol. 339, article b4531, 2009. View at Publisher · View at Google Scholar
  18. A. Nicolucci, G. De Berardis, M. Sacco, and G. Tognoni, “AHA/ADA vs. ESC/EASD recommendations on Aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions,” European Heart Journal, vol. 28, no. 16, pp. 1925–1927, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. J. A. Colwell, “Diabetes: does Aspirin use reduce cardiovascular risk in diabetes?” Nature Reviews Endocrinology, vol. 5, no. 4, pp. 188–190, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. M. Pignone, M. J. Alberts, J. A. Colwell et al., “Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation,” Circulation, vol. 121, no. 24, pp. 2694–2701, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. American Diabetes Association, “Aspirin therapy in diabetes (position statement),” Diabetes Care, vol. 27, supplement 1, pp. S72–S73, 2004. View at Google Scholar
  22. R. Altman, L. Carreras, R. Diaz et al., “Collaborative overview of randomised trials of antiplatelet therapy—I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients,” British Medical Journal, vol. 308, no. 6921, pp. 81–106, 1994. View at Google Scholar
  23. Antithrombotic Trialist's Collaboration, “Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients,” British Medical Journal, vol. 324, no. 7329, pp. 71–86, 2002. View at Google Scholar
  24. C. Watala, “Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus,” Current Pharmaceutical Design, vol. 11, no. 18, pp. 2331–2365, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Gent, “A randomised, blinded, trial of clopidogrel versus Aspirin in patients at risk of ischaemic events (CAPRIE),” The Lancet, vol. 348, no. 9038, pp. 1329–1339, 1996. View at Publisher · View at Google Scholar
  26. D. L. Bhatt, S. P. Marso, A. T. Hirsch, P. A. Ringleb, W. Hacke, and E. J. Topol, “Amplified benefit of Clopidogrel versus Aspirin in patients with diabetes mellitus,” American Journal of Cardiology, vol. 90, no. 6, pp. 625–628, 2002. View at Publisher · View at Google Scholar
  27. S. Yusuf, F. Zhao, S. R. Mehta, S. Chrolavicius, G. Tognoni, and K. K. Fox, “Effects of clopidogrel in addition to Aspirin in patients with acute coronary syndromes without ST-segment elevation,” New England Journal of Medicine, vol. 345, no. 7, pp. 494–502, 2001. View at Publisher · View at Google Scholar
  28. J. L. Anderson, C. D. Adams, E. M. Antman et al., “ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 2002 Guidelines for the management of Patients with Unstable angina/ non-ST-elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiographyand Interventions, and the Society of Thoracis Surgeons endorsed by the Amrican Association of cardiovascular and pulmonary Rehabilitation and the Society for Academic Emergency medicine,” Journal of the American College of Cardiology, vol. 50, no. 7, pp. e1–e157, 2007. View at Google Scholar
  29. A. Y. Gasparyan, T. Watson, and G. Y. H. Lip, “The role of Aspirin in cardiovascular prevention: implications of Aspirin resistance,” Journal of the American College of Cardiology, vol. 51, no. 19, pp. 1829–1843, 2008. View at Publisher · View at Google Scholar · View at PubMed
  30. S. Sanderson, J. Emery, T. Baglin, and A. L. Kinmonth, “Narrative review: Aspirin resistance and its clinical implications,” Annals of Internal Medicine, vol. 142, no. 5, pp. 370–380, 2005. View at Google Scholar
  31. D. J. Angiolillo, “Antiplatelet therapy in type 2 diabetes mellitus,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 14, no. 2, pp. 124–131, 2007. View at Publisher · View at Google Scholar · View at PubMed
  32. C. Watala, J. Pluta, J. Golanski et al., “Increased protein glycation in diabetes mellitus is associated with decreased Aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to Aspirin,” Journal of Molecular Medicine, vol. 83, no. 2, pp. 148–158, 2005. View at Publisher · View at Google Scholar · View at PubMed
  33. G. Di Minno and F. Violi, “Aspirin resistance and diabetic angiopathy: back to the future,” Thrombosis Research, vol. 113, no. 2, pp. 97–99, 2004. View at Publisher · View at Google Scholar · View at PubMed
  34. R. Ajjan, R. F. Storey, and P. J. Grant, “Aspirin resistance and diabetes mellitus,” Diabetologia, vol. 51, no. 3, pp. 385–390, 2008. View at Publisher · View at Google Scholar · View at PubMed
  35. A. M. Cerbone, N. MacArone-Palmieri, G. Saldalamacchia, A. Coppola, G. Di Minno, and A. A. Rivellese, “Diabetes, vascular complications and antiplatelet therapy: open problems,” Acta Diabetologica, vol. 46, no. 4, pp. 253–261, 2009. View at Publisher · View at Google Scholar · View at PubMed
  36. T. Geisler, N. Anders, M. Paterok et al., “Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation,” Diabetes Care, vol. 30, no. 2, pp. 372–374, 2007. View at Publisher · View at Google Scholar · View at PubMed
  37. D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo et al., “Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined Aspirin and clopidogrel treatment,” Diabetes, vol. 54, no. 8, pp. 2430–2435, 2005. View at Publisher · View at Google Scholar
  38. I. A. Ferreira, A. I. Mocking, M. A. Feijge et al., “Platelet inhibition by insulin is absent in type 2 diabetes mellitus,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 2, pp. 417–422, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. J. A. Colwell, “Is Aspirin effective in diabetic patients? Yes,” Journal of Thrombosis and Haemostasis, vol. 3, no. 12, pp. 2612–2614, 2005. View at Publisher · View at Google Scholar · View at PubMed
  40. C. Cimminiello, “Is Aspirin effective in diabetic patients? No,” Journal of Thrombosis and Haemostasis, vol. 3, no. 12, pp. 2615–2616, 2005. View at Publisher · View at Google Scholar · View at PubMed
  41. C. L. Campbell, S. Smyth, G. Montalescot, and S. R. Steinhubl, “Aspirin dose for the prevention of cardiovascular disease: a systematic review,” Journal of the American Medical Association, vol. 297, no. 18, pp. 2018–2024, 2007. View at Publisher · View at Google Scholar · View at PubMed
  42. A. D. Michelson, M. Cattaneo, J. W. Eikelboom et al., “Aspirin resistance: position paper of the working group on Aspirin resistance,” Journal of Thrombosis and Haemostasis, vol. 3, no. 6, pp. 1309–1311, 2005. View at Publisher · View at Google Scholar · View at PubMed
  43. G. Davì and F. Santilli, “Aspirin as antiplatelet agent in diabetes. PROS-,” European Journal of Internal Medicine, vol. 21, no. 3, pp. 149–153, 2010. View at Publisher · View at Google Scholar · View at PubMed
  44. C. Patrono and B. Rocca, “The future of antiplatelet therapy in cardiovascular disease,” Annual Review of Medicine, vol. 61, pp. 49–61, 2010. View at Publisher · View at Google Scholar · View at PubMed
  45. G. Di Minno, M. J. Silver, A. M. Cerbone, and S. Murphy, “Trial of repeated low-dose Aspirin in diabetic angiopathy,” Blood, vol. 68, no. 4, pp. 886–891, 1986. View at Google Scholar
  46. S. Wong, M. C. Morel-Kopp, Q. Chen, M. Appleberg, C. M. Ward, and D. R. Lewis, “Overcoming Aspirin resistance: increased platelet inhibition with combination Aspirin and clopidogrel and high dose Aspirin therapy in Aspirin resistant patients with peripheral vascular disease,” Thrombosis and Haemostasis, vol. 95, no. 6, pp. 1042–1043, 2006. View at Publisher · View at Google Scholar · View at PubMed
  47. D. J. Angiolillo, P. Capranzano, S. Goto et al., “A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study,” European Heart Journal, vol. 29, no. 18, pp. 2202–2211, 2008. View at Publisher · View at Google Scholar · View at PubMed
  48. S. B. King, S. C. Smith, J. W. Hirshfeld, A. K. Jacobs, D. A. Morrison, and D. O. Williams, “2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines,” Journal of the American College of Cardiology, vol. 51, no. 2, pp. 172–209, 2008. View at Publisher · View at Google Scholar · View at PubMed
  49. D. J. Angiolillo, S. B. Shoemaker, B. Desai et al., “A randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study,” Circulation, vol. 115, no. 6, pp. 708–716, 2007. View at Google Scholar
  50. S. D. Wiviott, E. Braunwald, D. J. Angiolillo et al., “Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38,” Circulation, vol. 118, no. 16, pp. 1626–1636, 2008. View at Publisher · View at Google Scholar · View at PubMed
  51. G. G. Neri Serneri, S. Coccheri, E. Marubini, and F. Violi, “Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study,” European Heart Journal, vol. 25, no. 20, pp. 1845–1852, 2004. View at Publisher · View at Google Scholar · View at PubMed